Early palliative care for patients with metastatic non-small-cell lung cancer.

By J. Temel, J. Greer, A. Muzikansky, E. Gallagher, S. Admane, V. Jackson, C. Dahlin, C. Blinderman, J. Jacobsen, W. Pirl and 2 more. New England Journal of Medicine, 2010

6,223 citations recorded by the source corpus.

Subfields: Oncology, Public Health, Environmental and Occupational Health, Surgery

View Paper: https://www.semanticscholar.org/paper/0cd2002df2a3b3cdf8d351b2a4a7273463c2f318

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. Hui
2. E. Bruera
3. K. Kerr
4. M. Hellmann
5. E. Stovall

In Public Health, Environmental and Occupational Health

1. E. Bruera
2. D. Hui
3. Laura A. Levit
4. Patricia A. Ganz
5. E. Balogh
6. Sharyl J Nass

Citations in the corpus

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “This confirmed the evidence from multiple randomized trials that included patients with cancer who showed an improvement in symptoms, including less anxiety and depression, higher satisfaction, less aggressive end-of-life care, and less caregiver distress.(108) In addition, a cluster RCT published s”
• Happy People Live Longer: Subjective Well-Being Contributes to Health and Longevity (2011, background): “Temel et al. (2010) conducted an experiment in which one group of terminal cancer patients received palliative care earlier than typical, compared to the control group which received palliative care at the standard time. The early-care patients had fewer depressive symptoms and lived almost three mo”
• American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. (2012, methodology): “They concluded that it was premature to develop a PCO.”
• Integration of oncology and palliative care: a Lancet Oncology Commission. (2018, background): “Gav gjennomslag for palliasjon i ASCO Bakitas 2009-2015 Temel 2010-2017 Zimmermann 2014 Vanbutsele 2018 Basch 2018 Integrasjon onkologi – palliasjon.”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “14-2-54) Improved 4 [85]”